LIGAND PHARMACEUTICALS INC
For the period ended Jun 30, 2025. Filed Aug 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 8, 2025
LGND$314.16+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except par value)
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $67,669 | $72,307 |
| Short-term investments | 177,351 | 183,858 |
| Accounts receivable, net | 41,288 | 38,376 |
| Inventory | 15,489 | 14,114 |
| Short-term portion of financial royalty assets, net | 10,276 | 10,025 |
| Income taxes receivable | 828 | 4,073 |
| Other current assets | 4,816 | 8,806 |
| Assets held for sale (Note 2) | 35,228 | — |
| Total current assets | 352,945 | 331,559 |
| Intangible assets, net | 250,133 | 266,648 |
| Goodwill | 101,541 | 105,250 |
| Long-term portion of financial royalty assets, net | 193,556 | 185,024 |
| Noncurrent derivative assets | 17,958 | 10,583 |
| Property and equipment, net | 3,632 | 15,133 |
| Lease right-of-use assets | 7,991 | 9,673 |
| Other investments | 10,908 | 10,908 |
| Deferred income taxes, net | 829 | 72 |
| Other assets | 9,111 | 6,924 |
| Total assets | $948,604 | $941,774 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $8,584 | $5,233 |
| Accrued liabilities | 17,464 | 27,906 |
| Income taxes payable | 305 | 1,199 |
| Deferred revenue | 111 | 1,278 |
| Current contingent liabilities | 1,465 | 206 |
| Current operating lease liabilities | 1,089 | 1,266 |
| Current finance lease liabilities | 24 | 24 |
| Liabilities related to assets held for sale (Note 2) | 35,692 | — |
| Total current liabilities | 64,734 | 37,112 |
| Long-term deferred revenue | — | 2,246 |
| Long-term contingent liabilities | 4,097 | 3,475 |
| Long-term operating lease liabilities | 4,629 | 5,815 |
| Deferred income taxes, net | 32,246 | 32,524 |
| Other long-term liabilities | 14,369 | 30,163 |
| Total liabilities | 120,075 | 111,335 |
| Commitments and contingencies | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at June 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 60,000 shares authorized; 19,411 and 19,106 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | 20 | 20 |
| Additional paid-in capital | 358,635 | 337,377 |
| Accumulated other comprehensive income (loss) | 8,494 | (5,942) |
| Retained earnings | 461,380 | 498,984 |
| Total stockholders' equity | 828,529 | 830,439 |
| Total liabilities and stockholders' equity | $948,604 | $941,774 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.